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Systemic sclerosis (SSc) is a multiorgan connective tissue disease characterized by autoantibody production and ﬁbroproliferative
stenosis of the microvasculature. The vascoluopathy associated with SSc is considered to be noninﬂammatory, yet frank
vasculitis can complicate SSc, posing diagnostic and therapeutic challenges. Here, we have reviewed the literature for reports
of small-, medium-, and large-vessel vasculitis occurring in SSc. Amongst 88 reported cases of vasculitis in SSc, patients with
ANCA-associated vasculitis appear to present a unique subclass in that they combined typical features of SSc with the renal
manifestation of ANCA-associated glomerulonephritis. Other vasculitic syndromes, including large-vessel vasculitis, Behcet’s
disease, cryoglobulinemia, and polyarteritis nodosa, are rarely encountered in SSc patients. ANCA-associated vasculitis needs
to be considered as a diﬀerential diagnosis in SSc patients presenting with renal insuﬃciency, as renal manifestations may result
from distinct disease processes and require appropriate diagnostic testing and treatment.
1.Introduction
Systemic sclerosis (SSc) is a connective tissue disease charac-
terizedbyﬁbrosisandvasculopathyinvolving multipleorgan
systems. Classiﬁcation into diﬀuse or limited cutaneous
forms depends on the extent of skin thickening, with the for-
mer aﬀecting areas proximal to the elbows or knees, and the
latterlimitedtothefaceanddistalextremities[1].Manyclin-
ical complications of SSc are due to dysfunction of vascular
beds throughout the body. Involvement of the microvascula-
ture leads to cutaneous and mucosal telangiectasias, digital
ulcers, and tissue ischemia. If medium-sized blood vessels
are involved, manifestations include gangrene, digital loss,
renal crisis, and pulmonary arterial hypertension [2]. While
occlusive vasculopathy is a well-recognized feature of SSc,
less is known about the occurrence and the consequences
of frank vascular inﬂammation. Albeit rare, typical vasculitis
with inﬂammatory inﬁltrates damaging blood vessels has
been reported in patients with SSc. Distinguishing between
noninﬂammatory vasculopathy and vasculitis can pose a
signiﬁcant diagnostic challenge in the absence of histologic
examination. Here, we review reported cases of large-,
medium-, and small-vessel vasculitis in association with SSc.
2.Vasculopathy versusVasculitis
The distinction between SSc vasculopathy and vasculitis
can be diﬃcult to make based on clinical presentation
alone, but knowledge of the underlying pathogenesis and
histopathologycanbeveryhelpful.Inthecurrentpathogenic
model of SSc, a vascular injury of unknown cause leads
to endothelial apoptosis and initiates the process of SSc
vasculopathy. Autoantibodies, reperfusion injury, infection,
and defects in vascular repair have all been implicated
as possible instigators [3]. Increased levels of endothelial
cells in the circulation have been cited as evidence that
the intactness of the vascular lining is jeopardized [3, 4].
Subsequent endothelial dysfunction results in the imbalance
of vasoactive factors: decreased levels of vasodilators such as
endothelial nitric oxide synthase and prostacyclin synthase,
as well as increased levels of the vasoconstrictor endothelin-
1 and vascular endothelial growth factor [5, 6]. Continuous
endothelial dysfunction likely contributes to activation of
adventitial ﬁbroblasts with resultant intimal proliferation,
eventual luminal narrowing, and tissue hypoxia [4, 7].
Histopathology of SSc vasculopathy reﬂects the underlying
pathogenesis, with myoﬁbroblast proliferation and matrix2 International Journal of Rheumatology
deposit in the subendothelial layer leading to oblitera-
tive thickening of vessel walls. Inﬂammatory inﬁltrates
are absent, and the internal elastic lamina remains intact
[8].
In contrast to vasculopathy, concurrent vasculitis in
SSc shows histopathologic evidence of inﬂammation, with
presence of mononuclear inﬁltrates and destruction of the
vascular wall. Notably, both vasculopathic and vasculitic
changes were seen in ﬁve of nine (55%) digital amputation
specimens from SSc patients, emphasizing that small vessel
vasculitis and stenosing vasculopathy may coexist [8]. Fur-
ther support has come from autopsy studies of SSc patients,
where 24% of 58 cases showed noninﬂammatory intimal
proliferation in two or more organs, but 9% had features of
inﬂammatory polyarteritis [9]. Thus, vasculitis is known to
occur even in the setting of a disease predisposing towards
vasculopathy,andhistologyisrequiredtodistinguishthetwo
pathogenic processes.
3.Large-VesselVasculitis
3.1. Giant Cell Arteritis. Giant cell arteritis is a common
vasculitis of the elderly involving large- and medium-sized
arteries, typically the temporal, ophthalmic, vertebral, and
axillary arteries as well as the aorta. The American College
of Rheumatology (ACR) criteria include at least three of
the following: (1) onset at age >50, (2) new headache,
(3) claudication of the jaw or tongue, (4) temporal artery
tenderness to palpation or decreased pulsation, (5) ESR
>50mm/h,and(6)temporalarterybiopsyshowingvasculitis
withmononuclearinﬂammatoryinﬁltrateorgranulomatous
inﬂammation with presence of giant cells [10]. Typical
histomorphologic ﬁndings include disruption of the internal
elastic lamina, thinning of the media, and occlusion of
the lumen by hyperplastic intima. Pathogenic studies have
established that giant cell arteritis is a T-cell driven disease
with participation of Th1 and Th17 lineages [11, 12].
Steroids remain the mainstay of therapy, with many cases
resolving after one to two years.
While giant cell arteritis is relatively common among
the vasculitides, it has only been reported in three cases
of concurrent SSc, all of which were women in their sixth
decade with limited skin involvement [13–15]( Table 1). Two
of the three had the classic presentation of headache, jaw
claudication, and elevated sedimentation rate (ESR), with
evidence of vessel wall inﬂammation and giant cells on
temporal artery biopsy. The case reported by Sari-Kouzel
was unusual in that the presenting symptom was pain and
discoloration of the right foot in the setting of normal
ESR. The lower extremity ischemia eventually progressed to
gangrene necessitating a below-the-knee amputation. While
SSc vasculopathy may have contributed to ischemic tissue
damage,thehistologyfromtheamputationspecimenyielded
evidence for vasculitis with the presence of inﬂammatory
inﬁltrates, giant cells in the vessel wall, and vascular lumen
obliteration. All patients were started on corticosteroids
(prednisolone or prednisone 30 to 80mg daily) with slow
taper over 5–6 months and resolution of symptoms.
3.2. Takayasu Arteritis. Takayasu arteritis is a relatively
rare large vessel vasculitis (incidence 0.4–2/million/year)
aﬀecting mostly young women of Asian origin although
the incidence among the middleaged with atherosclerosis
has been rising [20, 21]. The aorta and its main branches
are typically involved. ACR diagnostic criteria include at
least three of the following: (1) onset before age 40, (2)
claudication of an extremity, (3) decreased brachial artery
pulse, (4) >10mmHg in systolic blood pressure between
the arms, (5) bruit over the subclavian arteries or aorta,
and (6) stenosis/occlusion of the aorta, its major branches,
or large arteries in proximal upper or lower extremities
[22]. Similar to giant cell arteritis, the histopathology in
Takayasu arteritis shows mononuclear inﬁltrates in the vessel
wall, intimal thickening, destruction of elastic laminas,
giant cell formation, and expansion of the adventitial layer.
Elastic lamina destruction can lead to aneurysm formation
while transmural inﬂammation drives intimal proliferation,
adventitial scarring, and vascular lumen narrowing [23].
Treatmentwithsteroids leadsto remission in40% ofpatients
while 40% may relapse or require addition of a second drug
such as methotrexate or azathioprine [24, 25].
Four cases of Takayasu arteritis in the setting of SSc have
been reported. As the overwhelming majority of patients
with Takaysu arteritis are female, all four of these cases were
women, with ages ranging from 29 to 68 [16–19]. Three of
the patients had diﬀuse skin involvement. The presenting
symptoms included arm claudication and lightheadedness,
and physical examination revealed pulselessness in upper
extremities, blood pressure discrepancies >10mmHg as
measured in both arms, and in one case bruits involving the
neck and the back. Computed tomographic angiography in
all cases showed stenosis of various aortic branches, includ-
ing the brachiocephalic trunk, common carotid, subclavian,
celiac, and renal arteries. Thoracic outlet syndrome was
concurrently diagnosed in one case of arteritis, with imaging
demonstrating compression of the brachial artery by the
scalenus muscle. Two of the four patients were older than 40
yearsofageatthetimeofTakayasuarteritisdiagnosis,raising
the question whether they indeed had typical large vessel
vasculitis or whether a component of vessel-obstructive and
progressive atherosclerosis was part of the disease process.
The reports did not provide information about therapeutic
management.
4.Medium-and Small-VesselVasculitis
4.1. Polyarteritis Nodosa. Polyarteritis nodosa (PAN) is a
necrotizing vasculitis aﬀecting medium-sized vessels, with
a constellation of clinical ﬁndings that reﬂect multiorgan
involvement. It can be associated with hepatitis B viral
infection. PAN can be distinguished from the small-vessel
vasculitides such as microscopic polyangiitis by the absence
of antineutrophil cytoplasmic antibodies. The ACR diagnos-
tic criteria for PAN include at least three of the following:
(1) weight loss >4kg, (2) livedo reticularis, (3) testicular
pain or tenderness, (4) myalgias, weakness, or leg tenderness,
(5) mono- or polyneuropathy, (6) hypertension, (7) elevated
blood creatinine or urea, (8) serum hepatitis B antigen orInternational Journal of Rheumatology 3
Table 1: Seven cases of large-vessel vasculitis associated with SSc.
Case Vasculitis Age/Sex Age at
SSc Dx
SSc
type
Age at
Vasculitis
Dx
Presentation Diagnosis Outcome
Perez-Jimenez
et al. [13] GCA 68/F 68 L 70
Headache, jaw
claudication;
ESR 53
Temporal artery
biopsy: inﬂammatory
inﬁltrate, giant cells
Prednisone 60mg
daily x 5 weeks
then tapered.
Symptom-free at
5 years
Hupp [14] GCA 70/F ? L 70
Headache, jaw
claudication;
ESR 53
Temporal artery
biopsy: mononuclear
inﬁltrate, giant cells,
destruction of
internal elastic lamina
Prednisone 80mg
daily, tapered to
30mg daily over 5
months.
Symptom-free
and ESR 3 at
5m o n t h s .
Sari-Kouzel
et al. [15] GCA 64/F 49 L 64
Gangrene of right
2nd and 3rd toes;
ESR 14
Right knee
amputation biopsy:
mononuclear
inﬁltrate, giant cells,
vascular lumen
occlusion
Prednisolone
30mg daily,
tapered to 10mg
daily over 6
months.
Symptom-free at
6m o n t h s .
Passiu et al. [16] TA 29/F 29 D 21 ? ? ?
Yago et al. [17] TA 68/F 66 D 66
Vertigo, bruits in
neck, abdomen,
and back;
asymmetric
blood pressure
in arms
Stenosis of right
brachiocephalic
trunk, celiac and left
renal arteries
?
Kocabay et al.
[18] TA 48/F 48 D 47
Pulseless in both
arms with
intermittent
claudication
Obliteration of
bilateral subclavian
arteries distal to
vertebral artery
bifurcation
?
Kim et al. [19] TA 37/F 33 L 37 Weak left radial
pulse
Stenosis of right
common carotid
artery, right external
carotid artery,
thoracic and
abdominal aorta,
left brachial artery
compression by
scalenus muscle on
abduction
?
GCA = giant cell arteritis; TA = Takayasu’s arteritis; SSc = systemic sclerosis; L = limited; D = diﬀuse; ESR = erythrocyte sedimentation rate.
antibody, (9) aneurysms or occlusions of visceral arteries,
or (10) granulocytes on biopsy of small- or medium-sized
arteries[26].Arecentretrospectivestudyof348patientswith
PAN found general symptoms in 93.1%, neurologic involve-
ment in 79%, and skin involvement in about 50% [27].
Five-year relapse-free survival was 59.4% for nonhepatitis-
B-associated PAN and 67% for HBV-associated PAN.
Predictors of mortality included age greater than 65
years, new onset hypertension, and gastrointestinal manifes-
tationsrequiringsurgery.Treatmentreliesonglucocorticoids
in mild disease and a combination of glucocorticoids and
cyclophosphamide in moderate to severe disease.
Only one case of PAN has been described in a 28-year-
old woman with diﬀuse SSc, characterized by Raynaud’s
phenomenon and skin sclerosis over the hands, arms, and
chest [28]( Table 2). The patient developed brownish tender
nodules on her legs over three months. Biopsy of these
lesions revealed necrotizing arteritis in the deep dermis.
Despite the histologic appearance of the nodules, the patient
technically did not meet ACR criteria for PAN as she had
normal blood pressure and renal function, negative hepatitis
B serologies, and no other symptoms such as weakness or
neuropathy. Symptoms responded to weekly methotrexate at
20 mg and remainedstable at ﬁve months.4 International Journal of Rheumatology
4.2. Primary Angiitis of the Central Nervous System. Primary
angiitis of the central nervous system (PACNS) is a rare
poorly characterized entity aﬀecting small- and medium-
sized vessels of the central nervous system (CNS) but not
organs or vessels outside the CNS. In general, PACNS is dis-
tinguished from secondary CNS vasculitis with the exclusion
of infections, malignancy, systemic vasculitis or connective
tissue disease, or drug-induced vasculitis. Clinical presen-
tations of PACNS include confusion, new onset headache,
seizures, stroke or cerebral hemorrhage, and myelopathy
[35]. The duration from symptom onset to diagnosis can
range from 3 days to 3 years [36]. Multiple laboratory data
abnormalitiescanoccurbutnoneisspeciﬁcforthediagnosis,
with ESR described to be normal in a number of cases.
Characteristic changes on cerebral angiography include
multifocal segmental stenosis, dilatation, or occlusion of
small- and medium-sized leptomeningial and intracranial
vessels as well as formation of collateral vessels. Further
supportive evidence can be obtained from leptomeningeal
or parenchymal biopsies, which are speciﬁc but not sensitive
for vasculitis given the focal segmental nature of the disease;
therefore, a negative biopsy does not rule out the diagnosis.
Histology can show either granulomas in small vessel walls,
lymphocytic inﬁltrates, or necrotizing vasculitis [36]. The
rarity and heterogeneity complicate classiﬁcation, diagnosis,
and management. Calabrese and Mallek have proposed the
following diagnostic criteria for PACNS: (1) recent onset
of headache, confusion, or multifocal neurologic deﬁcits,
(2) cerebral angiographic changes suggestive of vasculitis,
(3) exclusion of systemic disease or infection, and (4)
leptomeningeal or parenchymal biopsy to conﬁrm vasculitis
and to exclude infection, malignancy, and noninﬂammatory
vascular occlusive disease [37]. Once the diagnosis is made,
aggressive treatment with high-dose steroids and cyclophos-
phamide has been suggested as the management of choice.
One case of PACNS has been described in SSc [29]
(Table 2). A 45-year-old woman with limited SSc diag-
nosed at age 21 presented with new onset headache for 3
days and confusion, later developing hypertension to the
230s/190s and generalized seizure. Computed tomography
of the head and spinal ﬂuid was unremarkable. Cerebral
angiogram showed an occluded medium-sized branch of
the middle cerebral artery as well as narrowing of several
distal medium-sized arteries in the anterior and middle
cerebral artery distribution. The patient was empirically
started on methylprednisolone 100mg IV every 4 hours for
suspicion of PACNS, and her mental status was normalized
within14hours.Arepeatcerebralangiogramoftheposterior
circulation showed multiple 1.5cm segments of smooth
narrowing in medium-sized arteries. The steroid dosage
could not be tapered below prednisone 50mg daily, as each
time the patient developed right facial and arm paresthesias
and expressive aphasia. Despite a negative leptomeningeal
biopsy, cyclophosphamide was started at 100mg daily and
gradually increased to 200mg daily with complete resolution
of symptoms.
4.3.MixedCryoglobulinemiaandCryoﬁbrinogenemia. Mixed
cryoglobulinemiaisthepresenceofpolyclonalimmunoglob-
ulins that precipitate in the serum with cold exposure, often
secondary to a connective tissue disease such as systemic
lupus erythematosus or Sjogren’s syndrome. The presence
of cryoglobulins (CGs) may be asymptomatic or may
lead to manifestations of the cryoglobulinemic syndrome,
including purpura, arthralgia, myalgia, glomerulonephritis,
and peripheral neuropathy [38]. The diagnosis of the latter
entails a combination of clinical presentation, laboratory
testing showing the presence of circulating cryoglobulins,
and histopathologic appearance such as leukocytoclastic
vasculitis (most common). Similarly, cryoﬁbrinogenemia is
the presence of cold-induced precipitants in the plasma but
notintheserum.Connectivetissuediseases,malignancy,and
infection have been known to be associated with this condi-
tion, which can be asymptomatic or can manifest as painful
ulcers, purpura, or perniosis, reﬂecting possible underlying
cold-induced thromboses, increased blood viscosity, or vas-
cular reactivity. The diagnosis of clinically signiﬁcant cry-
oﬁbrinogenemiarequiresnotonlycirculatingcryoﬁbrinogen
(CF) but also clinical features and histopathologic evidence
of small-vessel thrombosis and perivascular inﬁltrate [39].
For both mixed cryoglobulinemia and cryoﬁbrinogenemia,
treating the underlying disease (whether infection, connec-
tive tissue disease, or malignancy) can sometimes improve
symptoms. Plasmapheresis and immunosuppression with
glucocorticoids and/or cytotoxic therapy have also been used
in severe disease although with unclear eﬃcacy.
Connective tissue diseases have been associated with the
presence of both CG and CF, perhaps more so than CF alone
[40]. In the few studies and reports involving SSc, these cold-
induced precipitants do not appear to trigger symptoms. In
one study, one out of 19 patients with both CG and CF
carried the diagnosis of SSc [40]. In another study, 10 out
of 20 SSc patients had the presence of polyclonal IgG and
IgM cryoglobulins in the serum, but none exhibited clinical
signs of cryoglobulinemic syndrome [41]. In one report of
long-standing SSc with the presence of cryoglobulins (both
IgG and IgM), the patient presented with paresthesias, tran-
sient aphasia, vision changes, and delirium [30]( Table 2).
Cerebral angiogram was normal, and electroencephalogram
revealed generalized slowing of action potentials, and com-
puted tomography of the extremities revealed calcinosis.
Whileperipheralneuropathycanbeamanifestationofmixed
cryoglobulinemia, central nervous system involvement
would be highly unusual; therefore it, is unclear whether the
presenceofcryoglobulinsinthiscaseisanincidentalﬁnding.
Another man with long-standing SSc presented with sudden
onset gangrene in the ﬁngers and toes after cold exposure
and was found to have very elevated cryoﬁbrinogen [31].
He did not respond to prostaglandin E1 or subcutaneous
heparin and died shortly after presentation. No biopsy was
done to ascertain the etiology for the gangrene, therefore,
either underlying SSc vasculopathy or thrombosis from the
cryoﬁbrinogenemia could have been possible causes.
4.4. Behcet’s Disease. Behcet’s disease is characterized by
recurrent oral aphthous ulcers and other systemic manifes-
tations believed to be due to systemic vasculitis, including
genital aphthous ulcers, ocular disease, skin involvement,International Journal of Rheumatology 5
Table 2: Seven cases of medium- and-small vessel vasculitis associated with SSc.
Case Vasculitis Age/Sex Ag at
SSc Dx
SSc
type
Age at
Vasculitis
Dx
Presentation Diagnosis Outcome
Pathak and
Gobor [29] CNS 45/F 21 L 45
Headache,
confusion,
seizure, aphasia;
right face/arm/leg
numbness
Angiography with abrupt
cutoﬀ in MCA branch,
narrowing in ACA and
MCA branches;
leptomeningeal biopsy
negative
Improved with
methylprednisolone
then
cyclophosphamide
Kang et al.
[28] PAN 28/F 28 D 28 Brownish tender
nodules on legs
Skin biopsy: necrotizing
arteritis in deep dermis
Stable on weekly
methotrexate 20mg
Jim´ enez
L´ opez
et al. [30]
Mixed
CG 50/F 50 L 50
Paresthesias,
vision changes,
aphasia, delirium;
rash on lips,
palms, soles
Cryoglobulin
> 0.1mg/100mL
Electroencephalogram:
generalized slowing
Cerebral angiogram:
normal
?
B a r r e t te ta l .
[31] CF 49/M 38 L 49
Sudden onset
gangrene of
ﬁngers and toes;
confusion
Cryoﬁbrinogen 435 mg/L
(<40)
Died despite
Subcutaneous
heparin and
prostaglandin E1
Choy et al.
[32] BD 54/F 54 D 16
Oral/genital
ulcers, superﬁcial
throm-
bophlebitis, rash,
esophageal
dysmotility, no
tear production,
left knee arthritis
Grade II esophagitis ILD
with restrictive PFTs Rash
with pathergy
Unresponsive to
topical steroids; later
azathioprine 100mg
daily, eye drops,
D-penicillamine,
colchicine; arthritis
continued
Yokota et al.
[33] BD 62/M 57 L 60
Oral/genital
ulcers, erythema
nodosa,
esophageal and
gastric ulcers,
chronic hepatitis
C, pancytopenia
?
Esophageal ulcers
resistant to
prednisolone 30mg
daily;
died from pneumonia
Sugisaki et al.
[34] RPC 35/M 31 L 35
Left auricular
ulcer and
swelling;
polyarthralgia
MRI: partial defect in
nasal septum
Improved with
prednisolone 15mg
daily and not with
antibiotics
CNS = central nervous system vasculitis; PAN = polyarteritis nodosa; Mixed CG = mixed cryoglobulinemia; CF = cryoﬁbrinogenemia; BD = Behcet’s disease;
RPC = relapsing polychondritis; SSc = systemic sclerosis; L = limited; D = diﬀuse.
gastrointestinal ulcers, neurologic disease, and arthritis. It
is more common along the ancient Silk Road, with 0.11%
prevalence in Turkey and 2.6% per 100,000 in Southern
China [42]. Diagnosis is made based on clinical features
including presence of recurrent oral aphthae plus two of
the following without other systemic disease: (1) recurrent
genital aphthae, (2) eye lesions including uveitis or retinal
vasculitis, (3) skin lesions including erythema nodosum,
pseudovasculitis, papulopustular lesions, or acneiform nod-
ules, or (4) positive pathergy test [43]. Treatment for
mucocutaneous and joint disease includes colchicine (mixed
results), glucocorticoids, and other immunosuppressives
such as azathioprine. More serious disease with internal
organ involvement has been treated with cyclophosphamide
and high-dose steroids.
Two cases of Behcet’s disease with concurrent SSc have
been reported [32, 33]( Table 2). Recurrent oral and genital
ulcers were the predominant symptoms in both cases, and
neither had eye involvement. In the case of the 54-year-old
woman with diﬀuse SSc, the diagnosis of Behcet’s disease
was made based on recurrent oral and genital ulcers and
presence of pathergy; skin involvement was nonspeciﬁc [32].
Her more bothersome symptoms were related to her SSc
including restrictive lung disease, esophageal dysmotility,
and polyarthritis, as well as secondary Sjogren’s syndrome.
The recurrent ulcers initially responded well to azathioprine
100mg daily; later she was switched to colchicine with
unknown eﬀect. In the case of the 62-year-old man with
limited SSc based on biopsy-proven sclerodactyly, the pres-
ence of recurrent oral and genital ulcers as well as erythema6 International Journal of Rheumatology
nodosa led to the diagnosis of Behcet’s disease [33]. He had
concurrentchronichepatitisCcomplicatedbypancytopenia.
He later developed esophageal and gastric ulcers that were
felt to be consistent with enteric Behcet’s. These ulcers were
resistant to prednisolone 30mg daily.
4.5. Relapsing Polychondritis. Relapsing polychondritis
(RPC) is an inﬂammatory disease of unknown etiology
involving cartilagenous tissues in multiple organs, typically
theears,nose,eyes,respiratorytract,andjoints.Vascularand
neurologic complications have also been reported. Associa-
tion with systemic vasculitis, connective tissue disease, or
myelodysplastic syndrome occurs in up to one-third of the
cases. The original diagnostic criteria by McAdam required
three of six clinical manifestations: (1) bilateral auricular
chondritis, (2) nonerosive seronegative polyarthritis, (3)
nasal chondritis, (4) respiratory tract chondritis, (5) ocular
inﬂammation, or (6) cochlear and/or vestibular dysfunction
[44]. The criteria were later modiﬁed to include the presence
ofthreeormoreoftheabove,oneclinicalmanifestationwith
corroborating histology, or chondritis at more than two sites
responsive to steroids or Dapsone [45]. Given the rarity and
relapsing nature of the disease, treatment has been empiric,
with Dapsone and glucocorticoids favored for mild nonvis-
ceral disease, and high-dose steroids and possible adjunctive
immunosuppressants for organ-threatening disease.
Only one case of RPC has been reported in association
with SSc [34]( Table 2). A 35-year-old man with limited SSc
presented with a known nasal septal perforation presented
with left auricular swelling and polyarthralgia. The left
auricle later was ulcerated with drainage of pus and was felt
to be super infected with Pseudomonas aeruginosa.H o w e v e r ,
the ulcer did not improve with antibiotics but rather with
prednisolone 15mg daily.
5.ANCA-AssociatedVasculitis(AAV)
The spectrum of necrotizing small-vessel vasculitis known
as ANCA-associated vasculitis (AAV) includes Wegener’s
granulomatosis (WG), microscopic polyangiitis (MPA), and
Churg-Strauss syndrome (CSS). While formally classiﬁed
as small-vessel vasculitis, AAV can involve medium-sized
vessels. Cytoplasmic antineutrophil cytoplasmic antibodies
(c-ANCAs) directed against proteinase 3 (PR3) are more
commonly found in WGs whereas perinuclear ANCAs (p-
ANCA) targeting myeloperoxidase (MPO) are more fre-
quently seen in MPA and CSS. Variable organ involvement
makes diagnosis a challenge, with alveolar hemorrhage and
crescentic glomerulonephritis frequently occurring in WG
and MPA, while polyneuropathy can be seen in ANCA-
associated CSS [46]. Disease stage can range from localized
without end-organ damage to severe generalized with organ
failure. Treatment of generalized disease involves induction
with cyclophosphamide (whether oral or intravenous) fol-
lowed by maintenance with less toxic drugs such as azathio-
prine, methotrexate, or myclophenolate mofetil. Standard
therapy leads to remission in 90% to 94% of AAV patients
within six months although relapses frequently occur (18 to
40% in WG at 24 months) [47].
Of all the small vessel vasculitides, AAV is the most fre-
quentlyreportedinassociationwithSSc,raisingthequestion
whether an overlap syndrome exists that combines features
from both diseases. A study by Rho et al. found 31 reports
containing 63 cases of AAV in SSc up to 1994 [56]. Fifty
of the 63 cases provided suﬃcient clinical and laboratory
information and were included in the analysis. Eighty-
four percent were women with a mean age of 57.1 years.
Cases of limited and diﬀuse SSc were equally represented.
Autoantibody proﬁling showed 72% with positive ANA
(titers unknown), 70% with anti-Scl-70 antibody, and 72%
with positive anti-MPO antibody. The most common end-
organ involvement included kidneys (82%) and lungs (70%
had pulmonary ﬁbrosis). Outcomes were not described in
17/50 (34%), but analysis of the remaining cases yielded a 7-
year survival rate of 67.9%, with a high mortality rate within
the ﬁrst year. Furthermore, anti-Scl-70 antibody was found
to be a signiﬁcant predictor of developing AAV in SSc (OR
3.1, 95% conﬁdence interval 1.11-8.55, P value .031). There
was no diﬀerence in AAV occurrence between SSc subtypes
(P value .998), the presence of MPO versus. PR3 ANCA (P
value .196), or prior use of D-penicillamine (P value .143).
Inourreviewoftheliterature,wefoundelevenadditional
cases of AAV in SSc that were not cited as part of the Rho
study [48–55]( T a b l e s3 and 4). Seven (64%) were female
withameanageof53 ± 1 4y e a r s( r a n g ef r o m1 9t o7 1y e a r s ) .
SSc disease duration was known for 9 of the 11 cases, with
am e a no f4 . 4 9± 3.37 years (range from 0.42 to 10 years).
The time from SSc diagnosis to AAV onset was known for
10 cases and reached a mean of 3.85 ± 2.67 years (range
from 0.42 to 8 yrs). Seven patients (64%) had diﬀuse skin
involvement, and four (36%) were previously treated with
D-penicillamine.Renalinvolvementintheformofcrescentic
glomerulonephritisonrenalbiopsywasseenin9cases(82%)
while pulmonary ﬁbrosis was seen in 3 cases (27%). One
case was complicated by multiple cerebral hemorrhages [55].
Eight cases (88%) had positive ANA of at least 1:320, 5 cases
(45%) with positive anti-Scl-70 antibody, and only 1 case
(9%) with Anticentromere antibody. Almost all cases (91%)
had positive anti-MPO antibody while none had anti-PR3
antibody.
These ﬁndings highlight the importance of considering
crescentic glomerulonephritis related to AAV as a potential
cause of renal insuﬃciency in SSc patients. Classically,
scleroderma renal crisis occurs in up to 20% of patients with
diﬀuse SSc, and renal involvement manifesting as hyperten-
sion, proteinuria, or azotemia can be found in 45–60% [57].
However, causes other than scleroderma renal crisis should
be considered as a diﬀerential diagnosis, especially in settings
of normotension or ANCA positivity.
6. Conclusion
While lumen-occlusive vasculopathy is a prominent feature
of SSc, frank vasculitis may also occur. Coexistent SSc and
vasculitis have been reported for vessels of all sizes, either
before or after SSc diagnosis, and in either SSc subtype
(limited or diﬀuse). We found in the literature 88 casesInternational Journal of Rheumatology 7
Table 3: Eleven new cases of ANCA-associated vasculitis in SSc.
Case Age/Sex SSc
(yrs)
SSc to
AAV (yrs) SSc type Use of
D-penicillamine Renal Pulm
ﬁbrosis ANA Scl-70 MPO
Marlier et al.
[48] 62/M 5 5 L Yes CGN No ? ? +
Mart´ ınez Ara et
al. [49] 63/F 2 2 ? No CGN No 1:640 + +
Herrera-Esparza
et al. [50] 60/M 2 3 L No CGN No 1:2560 ? +
Hidalgo-
Tenorio et al.
[51]
48/F 1 1.5 D No None Yes 1:320 Neg +
71/F ? ? L No None No 1:320 Neg +
Kamen et al.
[52] 45/M 0.42 0.42 D No CGN No 1:2560 + +
19/M 5 5 D Yes CGN No 1:2560 + +
60/F 8 8 D No CGN No ? + +
Arnaud et al.
[53] 46/F 10 5.75 D Yes CGN Yes >1:1000 + +
Ramaswami et
al. [54] 52/F ? 0.83 D No CGN No 1:640 ? ?
Veetil and
Schimmer [55] 62/F 7 7 D Yes CGN No ? ? +
Note: All but Ramaswami had positive MPO, and none had PR3. SSc = Systemic sclerosis; L = Limited; D = Diﬀuse; CGN = crescentic glomerulonephritis; ?
= unknown.
Table 4: Characteristics of eleven cases of AAV in SSc.
Characteristic Number (%)
Sex (M/F) 4/7 (36%/64%)
Age (mean ± SD) 53 ± 14 (range from 19 to 71)
SSc duration (mean ± SD in yrs); 9 pts 4.49 ± 3.37 (range from 0.42 to 10 yrs)
SSc Dx to AAV dx (mean ± SD in yrs); 10 pts 3.85 ± 2.67 (range from 0.42 to 8 yrs)
SSc type (Diﬀuse/Limited) 7/3 (64%/27%)
D-penicillamine use 4 (36%)
Renal involvement 9 (82%) all with crescentic GN on Bx
Pulmonary involvement 2 (18%)
ANA + (> 1 : 320) 8 (88%)
Scl-70 + 5 (45%)
Anticentromere + 1( 9 % )
MPO + 10 (91%)
PR3 + 0
of vasculitis in SSc, with the vast majority being ANCA-
associated vasculitides (74 cases:63 cited by previous studies,
11 new). Rare cases of Takayasu’s arteritis (4 cases), giant
cell arteritis (3 cases), and Behcet’s disease (2 cases) have
been reported in patients aﬀected by SSc. Only single-
case reports have focused on other vasculitic syndromes,
including mixed cryoglobulinemia/cryoﬁbrinogenemia, pol-
yarteritis nodosa, primary angiitis of the central nervous
system, and relapsing polychondritis, suggesting that the
association between SSc and these disorders may be a chance
event. Although most patients exhibited classic symptoms
and signs for the respective vasculitides, conﬁrmation of
diagnoses and distinction from SSc rested on histology.
Prompt treatment with immunosuppression usually resulted
instabilizationofsymptoms.InSScpatientswithrenalinsuf-
ﬁciency and ANCA positivity, crescentic glomerulonephritis
related to AAV should be considered as a diﬀerential
diagnosis.8 International Journal of Rheumatology
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